

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Brookes
Date of last notice	13 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund
Date of change	28 November 2022
No. of securities held prior to change	Direct: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023; expire 14 November 2025 Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 300,000 Ordinary Shares & 65,658 Options with an exercise price of \$0.2476 and expire on 3 December 2022
Class	Ordinary Shares
Number acquired	Indirect: 150,000 under Entitlement Offer at \$0.035 each
Number disposed	Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$5,250
No. of securities held after change	Direct: 900,000 at \$0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023; expire 14 November 2025 Indirect – David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 450,000 Ordinary Shares & 65,658 Options with an exercise price of \$0.2476 and expire on 3 December 2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Purchased under the Entitlement Offer

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
--	-----

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.